SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Secret_Agent_Man who started this subject2/11/2004 1:28:57 PM
From: rkrw  Read Replies (2) of 508
 
Press Release Source: CoTherix, Inc.

James Pennington, M.D., Joins CoTherix Inc. as Chief Medical Officer
Wednesday February 11, 8:07 am ET

BELMONT, Calif., Feb. 11 /PRNewswire/ -- CoTherix, Inc. announced today the appointment of James E. Pennington, M.D., to the position of chief medical officer. Effective immediately, Dr. Pennington will lead the company's clinical development programs and strategic medical planning.
ADVERTISEMENT


"Jim will be a great asset to the CoTherix management team. His recent success in building an outstanding clinical development department at InterMune, plus his successful track record with FDA and international regulatory filings will be critical factors in our success as we work toward filing our New Drug Application (NDA) with the FDA for Ventavis® in the United States this year," said Scott Harkonen, chairman and chief executive officer of CoTherix.

Dr. Pennington is a 17 year veteran of the pharmaceutical industry and also has substantial academic background in medicine, having spent 11 years as a member of the Harvard Medical School faculty. Dr. Pennington most recently served as executive vice president of medical and scientific affairs at InterMune, Inc., where he was responsible for conducting over 30 Phase 2 and Phase 3 clinical trials. Prior to joining InterMune, Dr. Pennington was senior vice president of research, development and clinical affairs at Alpha Therapeutic Corporation and earlier spent 11 years with Bayer Corporation's Pharmaceutical Division as vice president of biological clinical research. Dr. Pennington received his B.A. and M.D. from the University of Oregon.

About CoTherix

CoTherix, Inc., formerly known as Exhale Therapeutics, Inc., is a privately held biopharmaceutical company with a clinical program for pulmonary hypertension. Investors include Alta Partners, BioAsia Investments, Frazier Healthcare Ventures, MPM Capital, Sofinnova Ventures, Sofinnova Partners, Spray Venture Partners and Thomas Weisel Healthcare Ventures. For more information, visit www.cotherix.com.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext